Patterns of use of systemic chemotherapy for Medicare beneficiaries with urothelial bladder cancer

Urologic Oncology: Seminars and Original Investigations

Volumn 29, Issue 3, 2011, Pages 252-258

  Porter, Michael P ^a   Kerrigan, Matthew C ^b   Donato, Bonnie M K ^c   Ramsey, Scott D ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Bristol Myers Squibb ^*

^c BRISTOL MYERS SQUIBB   (United States)

Author keywords

Bladder neoplasms; Delivery of health care; Drug therapy; Medicare; SEER program

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; GEMCITABINE; IFOSFAMIDE; METHOTREXATE; PACLITAXEL; VINBLASTINE;

AGED; ARTICLE; BLADDER CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURGERY; CYSTECTOMY; DATA BASE; DEMOGRAPHY; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICARE; MONOTHERAPY; OUTCOME ASSESSMENT; OUTPATIENT DEPARTMENT; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, TRANSITIONAL CELL; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; CYSTECTOMY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MEDICARE; MIDDLE AGED; NEOADJUVANT THERAPY; PHYSICIAN'S PRACTICE PATTERNS; SEER PROGRAM; SOCIOECONOMIC FACTORS; SURVIVAL RATE; TREATMENT OUTCOME; UNITED STATES; URINARY BLADDER NEOPLASMS;

EID: 79955731409     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2009.03.021     Document Type: Article

References (21)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2007. CA Cancer J Clin 2007, 57:43-66.
2. Ries L.A.G., Melbert D., Krapcho M., et al. SEER Cancer Statistics Review, 1975-2004 2007, National Cancer Institute, Bethesda, MD, [updated 2007; cited 2007 November 14]; Based on November 2006 SEER data submission, posted to the SEER web site, 2007]. http://seer.cancer.gov/csr/1975_2004.
3. Metts M.C., Metts J.C., Milito S.J., et al. Bladder cancer: A review of diagnosis and management. J Natl Med Assoc 2000, 92:285-294.
4. Sternberg C.N., Calabro F. Chemotherapy and management of bladder tumors. BJU Int 2000, 85:599-610.
5. Borden L.S., Clark P.E., Hall M.C. Bladder cancer. Curr Opin Oncol 2003, 15:227-233.
6. Neoadjuvant chemotherapy in invasive bladder cancer: A systematic review and meta-analysis. Lancet 2003, 361:1927-1934. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration.
7. Neoadjuvant chemotherapy in invasive bladder cancer: Update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol 2005, 48(2):202-205. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration, Discussion 5-6.
8. Dohan D., Schrag D. Using navigators to improve care of underserved patients: Current practices and approaches. Cancer 2005, 104:848-855.
9. SEER-Medicare Linked Database 2005 [updated 2005; cited 2005 March 20] National Cancer Institute. http://healthservices.cancer.gov/seermedicare/.
10. Hosmer D.W., Lemeshow S. Applied survival analysis: Regression modeling of time to event data 1999, John Wiley and Sons Inc, New York.
11. Deyo R.A., Cherkin D.C., Ciol M.A. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992, 45:613-619.
12. Bamias A., Efstathiou E., Moulopoulos L.A., et al. The outcome of elderly patients with advanced urothelial carcinoma after platinum-based combination chemotherapy. Ann Oncol 2005, 16:307-313.
13. Crivellari D., Bonetti M., Castiglione-Gertsch M., et al. Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: The International Breast Cancer Study Group Trial VII. J Clin Oncol 2000, 18:1412-1422.
14. Bladder Cancer (PDQ®): Treatment National Cancer Institute, [updated 2007; cited 2007 November 15]; Website]. http://www.cancer.gov/cancertopics/pdq/treatment/bladder/HealthProfessional/.
15. Grossman H.B., Natale R.B., Tangen C.M., et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003, 349:859-866.
16. Vaughn D.J., Malkowicz S.B., Zoltick B., et al. Paclitaxel plus carboplatin in advanced carcinoma of the urothelium: An active and tolerable outpatient regimen. J Clin Oncol 1998, 16:255-260.
17. Redman B.G., Smith D.C., Flaherty L., et al. Phase II trial of paclitaxel and carboplatin in the treatment of advanced urothelial carcinoma. J Clin Oncol 1998, 16:1844-1848.
18. von der Maase H., Hansen S.W., Roberts J.T., et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000, 18:3068-3077.
19. Clinical Practice Guidelines in Oncology: Bladder Cancer, ver. 1.2007 National Comprehensive Cancer Network, [updated 2007; cited 2007 November 15]; Website]. http://www.nccn.org/professionals/physician_gls/PDF/bladder.pdf.
20. Sternberg C.N., Donat S.M., Bellmunt J., et al. Chemotherapy for bladder cancer: Treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer. Urology 2007, 69(1 Suppl):62-79.
21. Warren J.L., Harlan L.C., Fahey A., et al. Utility of the SEER-Medicare data to identify chemotherapy use. Medical Care 2002, 40(8 Suppl):IV-55-IV-61.